从心肌病到心力衰竭的进展与减少的喷射分数:一个CORIN缺陷的过程
Jun-Yan Kan1, Dong-Chen Wang1, Zi-Hao Jiang1
1Division of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Heliyon
|September 24, 2024
概括
这项研究揭示了心肌病的两个分子亚型,其中一个群体显示出益菌性特征和不良预后. CORIN基因表达与疾病进展有关,可能是心力衰竭的治疗点.
科学领域:
- 心血管研究研究心血管研究
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 心肌病,包括缩性心肌病 (HCM) 和扩张性心肌病 (DCM),是导致心力衰竭 (HF) 的异质性心肌疾病.
- 了解分子异质性对于预后和治疗策略至关重要.
研究的目的:
- 使用转录基因数据探索HCM和DCM内的分子分层.
- 为了确定疾病进展和心脏纤维化潜在的生物标志物.
- 研究CORIN在心肌病进展中的作用.
主要方法:
- 对HCM和DCM的公开可用的微阵列和RNA测序 (RNA-seq) 数据集的分析.
- 非负矩阵因子化 (NMF) 的应用用于分子亚型.
- 丰富分析用于定义亚型的生物特征.
- 使用孟德尔随机化和体外实验验的验证.
主要成果:
- 在心肌病中,NMF确定了两个不同的分子.
- 鉴定出一种与心力衰竭 (心力衰竭与减少喷射分数 (HFrEF),低CORIN表达,纤维细胞激活,减少喷射分数 (LVEF) 和更糟糕的结果相关的益菌菌群 (集群1).
- 过度表达CORIN减少了TGFβ1诱导的心脏纤维细胞中的纤维化标志物.
结论:
- 心肌病表现出显著的分子异质性,通过转录组分析可以识别出不同的亚型.
- 科林在HCM,DCM和HFrEF的进展中发挥着作用,表明其作为治疗点的潜力.
- 需要进一步的研究来验证亚型,并探索CORIN的下游途径.
更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:29Pathophysiology of Cardiac Performance
601
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
601
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:22Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
01:26Heart Failure Drugs: Inotropic Agents
539
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
539